PIN11 Pharmacotherapy of Acute Bronchitis in Clinics: Results of Pharmacoepidemical Research

Abstract

Perform pharmacoepidemical analysis on actual practice when using antibacterial therapy among adults with acute bronchitis. We have analyzed 572 cases of acute bronchitis among patients receiving clinical treatment in four hospitals located in Moscow, Nizhniy Novgorod, St. Petersburg and Kazan. An individual registration folder featuring patient's demographic data, accompanying diseases, use of antimicrobial treatment, dose regimes and methods and length of treatment was filed for pharmacoepidemical research. The average age of patients was 39.8±5,7 years with 74% of men and 26% of women. Antibiotics were used in 85.7% of all cases. In Nizhniy Novgorod antimicrobial pills were given to 85% of patients while the number of such patients in Moscow and St. Petersburg amounted to 88.5% and 81.5% respectively. In Kazan all the patients received antimicrobial drugs. The most frequent drugs were macrolides (45.8%), inhibitor-protected penicillin (43.7%) and fluoroquinolines (ciprofloxacin) (4.9%). The less frequent ones were doxycycline (1.6%) and amoxicillin (1.8%) and ampicillin (2.2%). The most frequent macrolid was azitromicyn (33.7%) as well as clarythromycin (8.6%) and erythromycin (3.5%). As a result the actual practice of clinical treatment of acute bronchitis among adults majorly requres the use of antibacterial wide spectrum drugs (85.7%). The frequency of such therapy was high in all hospitals regardless of their locations. The use of antibiotics when treating virus etiology is obviously wrong and leads to the increase of non-desired consequences, higher cost of treatment and might be accompanied by the growing number of antibiotic resistant microorganisms. The above-mentioned data requires to create and practice methods aimed at the reduction of antimicrobial drug-taking for patients with acute bronchitis in clinical treatments.